SCHEDULE: CVI Investments, Heights Capital Report 9.9% Salarius Stake

CVI Investments, managed by Heights Capital Management, disclosed a 9.9% beneficial ownership stake in Salarius Pharmaceuticals, Inc., totaling 362,499 shares.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Salarius Pharmaceuticals, Inc.
• The Reporting Persons beneficially own an aggregate of 362,499 shares of Salarius Pharmaceuticals' common stock.
• This ownership represents 9.9% of the class of securities.
• The shares beneficially owned consist of 300,000 common shares and additional shares issuable upon the exercise of warrants.
• Warrants are subject to a blocker provision, preventing exercise if beneficial ownership would exceed 9.99%.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and exercises shared voting and dispositive power over the reported shares.
• As of the completion of an offering referenced in a prospectus filed on November 12, 2025, Salarius Pharmaceuticals had 3,566,117 shares outstanding.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a significant institutional investment.

Positives

• A significant institutional investor, CVI Investments, Inc., holds a substantial 9.9% stake in Salarius Pharmaceuticals, indicating a notable investment.
• The investment is managed by Heights Capital Management, Inc., a professional investment firm.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Salarius Pharmaceuticals, Inc.'s future outlook.

Management Comments

• Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing is a standard disclosure of a significant equity stake by institutional investors in a publicly traded company. It reflects an investment decision by CVI Investments and Heights Capital Management in Salarius Pharmaceuticals, a common occurrence in the financial markets, but does not provide broader industry trend analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, which can influence investor perception and potentially liquidity.
• Company Management: Awareness of a large, passive institutional investor holding a substantial stake.

Key Dates

Keywords

Salarius Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Equity Stake